Novo Nordisk Resubmits BLA for Awiqli® (Insulin Icodec) Once-Weekly Basal Insulin

Novo Nordisk has announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin for adults with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the US, offering an alternative to daily injections and potentially reducing annual basal insulin injections from 365 to just 52.

Anna Windle, PhD, Senior VP, Clinical Development, Medical and Regulatory Affairs, said:

"With this resubmission, we're one step closer to offering adults with type 2 diabetes a new treatment option that could simplify their basal insulin regimen. The ONWARDS clinical program supports our hope that Awiqli® can help streamline insulin therapy."

The ONWARDS phase 3a program included five randomized, active-controlled, treat-to-target trials involving ~4,000 adults with type 2 diabetes. Across these studies, Awiqli® was evaluated against daily basal insulin, with the primary endpoint measuring change in A1C from baseline.

About Awiqli®

Awiqli® is an investigational once-weekly basal insulin analog designed to cover basal insulin requirements for a full week with a single subcutaneous injection. It is already approved in the EU and 12 other countries, with additional regulatory filings underway.

About Novo Nordisk

Founded in 1923 and headquartered in Denmark, Novo Nordisk is a global healthcare leader dedicated to combating serious chronic diseases, with a particular heritage in diabetes. The company employs ~78,400 people across 80 countries and markets products in ~170 countries.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!